AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20836951 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartbur
Number of subjects: 24
Study 20836951 — intervention group
Group type: COMPARATOR
Intervention: Carbide bur
Number of subjects: 24
Study 18477490 — intervention group
Group type: EXPERIMENTAL
Intervention: NGM/EE (n=1506)
Number of subjects: 2563
Study 18477490 — intervention group
Group type: COMPARATOR
Intervention: norethindrone acetate/EE (n=1057)
Number of subjects: 2563
Study 21396140 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 g of fructose/d for 4 weeks
Number of subjects: 20
Study 21396140 — intervention group
Group type: COMPARATOR
Intervention: 150 g of glucose/d for 4 weeks
Number of subjects: 20
Study 16139347 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritually based booklet
Number of subjects: 108
Study 16139347 — intervention group
Group type: COMPARATOR
Intervention: Demographically targeted booklet (secular)
Number of subjects: 108
Study 12127050 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthrax vaccine (specific lots containing squalene)
Number of subjects: 25
Study 12127050 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthrax vaccine (general AVIP participants)
Number of subjects: 25
Study 12127050 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-vaccinated personnel)
Number of subjects: 25
Study 12127050 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimmunization sera from AVIP personnel
Number of subjects: 25
Study 12127050 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-vaccination sera from AVIP personnel
Number of subjects: 25
Study 9843287 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cue triggering with 75 ml of contrast agent at 1.5 ml/sec
Number of subjects: 120
Study 9843287 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated ROI threshold triggering with 75 ml of contrast agent at 1.5 ml/sec
Number of subjects: 120
Study 9843287 — intervention group
Group type: COMPARATOR
Intervention: Control group with 150 ml of contrast agent at 1 ml/sec
Number of subjects: 120
Study 8078551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine 100 mg/m²/day for 5 days by continuous infusion
Number of subjects: 693
Study 8078551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine 400 mg/m²/day for 5 days by continuous infusion
Number of subjects: 693
Study 8078551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine 3 g/m² in a 3-hour infusion every 12 hours on days 1, 3, and 5
Number of subjects: 693
Study 8078551 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 693
Study 2586471 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser irradiation (50mW)
Number of subjects: 124
Study 2586471 — intervention group
Group type: COMPARATOR
Intervention: No laser irradiation (control)
Number of subjects: 124
Study 2586471 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power laser for microvascular anastomosis
Number of subjects: 124
Study 53506 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece
Number of subjects: 50
Study 53506 — intervention group
Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 50
Study 11515714 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPRISAN
Number of subjects: 82
Study 11515714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 30787295 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injections of modified mRNA encoding VEGF‐A
Number of subjects: 0
Study 30787295 — intervention group
Group type: COMPARATOR
Intervention: Buffered saline placebo
Number of subjects: 0
Study 28106245 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,700 mg/day) + active lifestyle intervention
Number of subjects: 2000
Study 28106245 — intervention group
Group type: COMPARATOR
Intervention: Placebo + active lifestyle intervention
Number of subjects: 2000
Study 28106245 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,700 mg/day) alone
Number of subjects: 2000
Study 28106245 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 2000
Study 26552715 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized weaning from CPAP
Number of subjects: 41
Study 26552715 — intervention group
Group type: COMPARATOR
Intervention: Standardized weaning from CPAP (post-intervention)
Number of subjects: 41
Study 24122176 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1.5 g)
Number of subjects: 9
Study 24122176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 23019830 — intervention group
Group type: EXPERIMENTAL
Intervention: School environment
Number of subjects: 60
Study 23019830 — intervention group
Group type: COMPARATOR
Intervention: Hospital dental setup
Number of subjects: 60
Study 20175270 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1%
Number of subjects: 39
Study 20175270 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 0.09%
Number of subjects: 39
Study 20175270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 17427914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for chronic nightmares
Number of subjects: 27
Study 17427914 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 27
Study 16268466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (24 mg twice daily)
Number of subjects: 1223
Study 16268466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1223
Study 16268466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 1223
Study 12619264 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing pyrophosphate (1%) and tripolyphosphate (1%)
Number of subjects: 28
Study 12619264 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 28
Study 10347985 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 microg rgp160 every 3 months for 3 years
Number of subjects: 835
Study 10347985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (alum adjuvant alone)
Number of subjects: 835
Study 7564328 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg Ro 40‐5967 in 60 min
Number of subjects: 39
Study 7564328 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg Ro 40‐5967 in 30 min
Number of subjects: 39
Study 7564328 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg Ro 40‐5967 in 15 min
Number of subjects: 39
Study 7564328 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg Ro 40‐5967 in 30 min (two simultaneous doses of 40 mg)
Number of subjects: 39
Study 7564328 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg Ro 40‐5967 in 30 min (one arm)
Number of subjects: 39
Study 7564328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 1682645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa octavalent O‐polysaccharide‐toxin A conjugate vaccine
Number of subjects: 22
Study 6185060 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide at a dose of 0.2 mg/kg/day
Number of subjects: 50
Study 6185060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30592390 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated umbilical cord-derived mesenchymal stromal cells (UC-MSCs) at baseline and 6 months (20 × 10^6 × 2)
Number of subjects: 26
Study 30592390 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose umbilical cord-derived mesenchymal stromal cells (UC-MSCs) at baseline (20 × 10^6)
Number of subjects: 26
Study 30592390 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid at baseline and 6 months
Number of subjects: 26
Study 28764646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Number of subjects: 59
Study 28764646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 27378488 — intervention group
Group type: EXPERIMENTAL
Intervention: High extratextual engagement strategies including verbal responsiveness
Number of subjects: 0
Study 27378488 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate extratextual engagement strategies including verbal responsiveness
Number of subjects: 0
Study 27378488 — intervention group
Group type: EXPERIMENTAL
Intervention: Low extratextual engagement strategies including verbal responsiveness
Number of subjects: 0
Study 25256258 — intervention group
Group type: EXPERIMENTAL
Intervention: Abediterol 5 μg
Number of subjects: 0
Study 25256258 — intervention group
Group type: EXPERIMENTAL
Intervention: Abediterol 10 μg
Number of subjects: 0
Study 25256258 — intervention group
Group type: EXPERIMENTAL
Intervention: Abediterol 25 μg
Number of subjects: 0
Study 25256258 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 0
Study 25256258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21450214 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (20,000 international units subcutaneously every 2 weeks, extended to every 4 weeks based on Hb levels)
Number of subjects: 157
Study 21450214 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 157
Study 21450214 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 157
Study 18375537 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg icatibant (group B)
Number of subjects: 41
Study 18375537 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 microg icatibant (group C)
Number of subjects: 41
Study 18375537 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 41
Study 17241864 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing peginterferon alfa-2a dose to < or =60%
Number of subjects: 936
Study 17241864 — intervention group
Group type: COMPARATOR
Intervention: Full-dose peginterferon alfa-2a (> or =98%) with ribavirin dose reduced to < or =60%
Number of subjects: 936
Study 17241864 — intervention group
Group type: COMPARATOR
Intervention: Full-dose peginterferon alfa-2a with prematurely discontinued ribavirin
Number of subjects: 936
Study 15096814 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 19
Study 15096814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 12061970 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine with pyrimethamine-sulfadoxine (AQPS)
Number of subjects: 303
Study 12061970 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 303
Study 12061970 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine with pyrimethamine-sulfadoxine (CQPS)
Number of subjects: 303
Study 12061970 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine (AQ)
Number of subjects: 303
Study 9794671 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg of misoprostol
Number of subjects: 120
Study 9794671 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg of misoprostol
Number of subjects: 120
Study 9794671 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg of misoprostol
Number of subjects: 120
Study 9794671 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg of misoprostol
Number of subjects: 120
Study 9794671 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of 400 microg and 600 microg
Number of subjects: 120
Study 9794671 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of 600 microg and 800 microg
Number of subjects: 120
Study 7697848 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg rPF4
Number of subjects: 18
Study 7697848 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg rPF4
Number of subjects: 18
Study 7697848 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg rPF4
Number of subjects: 18
Study 7697848 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg/kg rPF4
Number of subjects: 18
Study 7697848 — intervention group
Group type: EXPERIMENTAL
Intervention: rPF4 administration
Number of subjects: 18
Study 2665662 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein based formula
Number of subjects: 173
Study 2665662 — intervention group
Group type: COMPARATOR
Intervention: Whey based formula
Number of subjects: 173
Study 856012 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 13
Study 856012 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 13
Study 31910895 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (10 mg)
Number of subjects: 30
Study 31910895 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (16 mg)
Number of subjects: 30
Study 31910895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30279028 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program and telephone call follow-up
Number of subjects: 116
Study 30279028 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 116
Study 28301264 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy with a median prescription dose of 70 Gy
Number of subjects: 125
Study 28301264 — intervention group
Group type: COMPARATOR
Intervention: Pre-existing cardiac disease
Number of subjects: 125
Study 28301264 — intervention group
Group type: COMPARATOR
Intervention: Mean heart dose
Number of subjects: 125
Study 28301264 — intervention group
Group type: COMPARATOR
Intervention: Disease progression
Number of subjects: 125
Study 28301264 — intervention group
Group type: COMPARATOR
Intervention: Grade ≥ 3 cardiac events
Number of subjects: 125
Study 25935340 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hyperosmotic treatment with sodium chloride 5% ophthalmic ointment (Muro‐128)
Number of subjects: 248
Study 25935340 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (no hyperosmotic treatment)
Number of subjects: 248
Study 23806384 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate (250 ml beetroot juice)
Number of subjects: 24
Study 23806384 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium nitrate capsules (KNO3, 8 mmol)
Number of subjects: 24
Study 23806384 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 24
Study 21457238 — intervention group
Group type: EXPERIMENTAL
Intervention: telcagepant + ibuprofen 280 mg + ibuprofen 400 mg
Number of subjects: 683
Study 21457238 — intervention group
Group type: EXPERIMENTAL
Intervention: telcagepant + acetaminophen 280 mg + acetaminophen 1000 mg
Number of subjects: 683
Study 21457238 — intervention group
Group type: EXPERIMENTAL
Intervention: telcagepant 280 mg
Number of subjects: 683
Study 21457238 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 683
Study 19837304 — intervention group
Group type: COMPARATOR
Intervention: Platelet-rich plasma (PRP) alone
Number of subjects: 18
Study 19837304 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) with resorbable collagen membrane (Bio-Gide)
Number of subjects: 18
Study 17702703 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus an additional session of standing practice
Number of subjects: 17
Study 17702703 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 17
Study 15383482 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tissue plasminogen activator (tPA) if treatment is initiated within 3 h of symptom onset
Number of subjects: 0
Study 15383482 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy for patients with extensive and clearly identifiable hypodensity on CT
Number of subjects: 0
Study 15383482 — intervention group
Group type: COMPARATOR
Intervention: IV tPA for unselected patients with AIS of > 3 h but < 6 h
Number of subjects: 0
Study 15383482 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 0
Study 15383482 — intervention group
Group type: COMPARATOR
Intervention: Full-dose anticoagulation with IV or subcutaneous heparins or heparinoids
Number of subjects: 0
Study 15383482 — intervention group
Group type: EXPERIMENTAL
Intervention: Early aspirin therapy, 160 to 325 mg qd
Number of subjects: 0
Study 15383482 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic low-dose subcutaneous heparin or low molecular weight heparins or heparinoids for AIS patients with restricted mobility
Number of subjects: 0
Study 15383482 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression devices or elastic stockings for patients with contraindications to anticoagulants
Number of subjects: 0
Study 15383482 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression for patients with acute intracerebral hematoma
Number of subjects: 0
Study 15383482 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet agent treatment (including aspirin, combination of aspirin and extended-release dipyridamole, or clopidogrel) for noncardioembolic stroke or TIA
Number of subjects: 0
Study 15383482 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aspirin and extended-release dipyridamole over aspirin
Number of subjects: 0
Study 15383482 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel over aspirin for noncardioembolic stroke or TIA
Number of subjects: 0
Study 15383482 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel for patients allergic to aspirin
Number of subjects: 0
Study 15383482 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oral anticoagulation for patients with atrial fibrillation and a recent stroke or TIA
Number of subjects: 0
Study 15383482 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin or low molecular weight heparin for patients with venous sinus thrombosis during the acute phase
Number of subjects: 0
Study 11422739 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion
Number of subjects: 9
Study 11422739 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion with AT1R blockade
Number of subjects: 9
Study 11422739 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 9
Study 9865645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin hydrochloride, 400 mg every 12 hours, and metronidazole hydrochloride, 500 mg every 6 hours
Number of subjects: 84
Study 9865645 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin sulfate, 2.5 mg/kg every 12 hours, and metronidazole hydrochloride, 500 mg every 6 hours
Number of subjects: 84
Study 7878282 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (IS-5-MN) 40 mg/12 hours
Number of subjects: 20
Study 7878282 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (IS-5-MN) 40 mg/8 hours
Number of subjects: 20
Study 7878282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2368896 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 0
Study 2368896 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study 383704 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 28
Study 383704 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 28
Study 383704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31613346 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-reduced Mediterranean diet, physical activity promotion, and behavioral support (n=3406)
Number of subjects: 6874
Study 31613346 — intervention group
Group type: COMPARATOR
Intervention: Energy-unrestricted Mediterranean diet (control group, n=3468)
Number of subjects: 6874
Study 31613346 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 6874
Study 28844985 — intervention group
Group type: EXPERIMENTAL
Intervention: FAmily CEntered disease-specific advance care planning (ACP) for teens with cancer (FACE-TC)
Number of subjects: 260
Study 28844985 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 260
Study 25888180 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic checklist implementation
Number of subjects: 810
Study 22859496 — intervention group
Group type: COMPARATOR
Intervention: 180 μg PegIFN for 48 weeks
Number of subjects: 128
Study 22859496 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 μg PegIFN for 48 weeks followed by 135 μg weekly for an additional 48 weeks
Number of subjects: 128
Study 22859496 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 μg PegIFN plus lamivudine for 48 weeks then 135 μg PegIFN for 48 weeks
Number of subjects: 128
Study 21474574 — intervention group
Group type: EXPERIMENTAL
Intervention: SHSe reduction coaching
Number of subjects: 201
Study 21474574 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study 20234035 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (2.25 g) plus policosanol (10 mg) for 21 days
Number of subjects: 18
Study 20234035 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oleic sunflower oil)
Number of subjects: 18
Study 17823447 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat fermented milk enriched with 0.8 g plant sterol (PS) ester per portion, consumed daily for 6 weeks
Number of subjects: 194
Study 17823447 — intervention group
Group type: COMPARATOR
Intervention: Control low-fat fermented milk, consumed daily for 6 weeks
Number of subjects: 194
Study 15061267 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT images using fan-beam collimators with scatter and attenuation corrections
Number of subjects: 11
Study 15061267 — intervention group
Group type: COMPARATOR
Intervention: SPECT images using parallel-hole collimators without any correction
Number of subjects: 11
Study 11231850 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 20
Study 11231850 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 20
Study 11231850 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon
Number of subjects: 20
Study 11231850 — intervention group
Group type: EXPERIMENTAL
Intervention: First assistant
Number of subjects: 20
Study 11231850 — intervention group
Group type: EXPERIMENTAL
Intervention: More experienced surgeon
Number of subjects: 20
Study 11231850 — intervention group
Group type: EXPERIMENTAL
Intervention: Less experienced surgeon
Number of subjects: 20